NAPLEX Quiz: Medication Error Reporting

What this quiz covers

This quiz focuses on Medication Error Reporting, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Monitoring oversight: failure to monitor vancomycin exposure and renal function appropriately, contributing to nephrotoxicity risk (correct answer)
2. Wrong drug dispensed: vancomycin should be replaced with amoxicillin-clavulanate in all cellulitis cases
3. Incorrect dose: vancomycin must always be dosed at 500 mg every 6 hours for adults
4. Wrong procedure: the issue should not be documented because it could reflect poorly on the care team

Explanation: Medication error identification and reporting target inadequate therapeutic monitoring for nephrotoxic agents like vancomycin to prevent renal injury. The key patient-specific factor is the absence of vancomycin levels and serial creatinine checks, allowing undetected accumulation and nephrotoxicity. Choice A best addresses the error as it identifies the monitoring oversight contributing to rising creatinine. Choice B is incorrect because vancomycin is appropriate for cellulitis, and choice C is suboptimal as the dose aligns with guidelines. Choice D is wrong since documentation is essential for accountability. For similar errors, follow pharmacokinetic monitoring protocols. Reporting encourages standardized ordering sets.

Question 2

1. Interaction oversight: phenytoin may reduce rivaroxaban exposure via enzyme induction, increasing thrombosis risk; pharmacist should intervene and document/report (correct answer)
2. Omission error: failure to add aspirin 325 mg daily to rivaroxaban for clot treatment
3. Monitoring oversight: failure to order routine INR monitoring for rivaroxaban therapy
4. Misidentification: phenytoin increases rivaroxaban levels and therefore reduces bleeding risk

Explanation: Medication error identification and reporting involve unrecognized inducer-inhibitor interactions affecting anticoagulant efficacy. The key patient-specific factor is phenytoin's CYP3A4 induction reducing rivaroxaban exposure, heightening thrombosis risk in DVT treatment. Choice A best addresses the error by highlighting the interaction oversight and need for intervention and reporting. Choice B is incorrect as aspirin addition isn't standard for DVT, and choice C is suboptimal since INR isn't used for rivaroxaban. Choice D is wrong because phenytoin decreases rivaroxaban levels. In practice, check for enzyme inducers and suggest alternatives. Reporting improves interaction database utilization.

Question 3

1. Wrong drug/formulation dispensed: metoprolol tartrate was dispensed instead of metoprolol succinate, creating incorrect release characteristics and dosing (correct answer)
2. Monitoring oversight: failure to obtain an INR before starting metoprolol
3. Misidentification: albuterol use makes beta-blockers always contraindicated, so dispensing any metoprolol is an error
4. Wrong procedure: do not document the incident unless the patient is hospitalized

Explanation: Medication error identification and reporting capture formulation mix-ups affecting drug release and therapeutic control. The key patient-specific factor is dispensing metoprolol tartrate instead of succinate, altering pharmacokinetics for once-daily hypertension management. Choice A best addresses the error as it specifies the wrong formulation dispensing, impacting efficacy. Choice B is incorrect since INR isn't relevant for metoprolol, and choice C is suboptimal as beta-blockers can be used cautiously with albuterol. Choice D is wrong because documentation is required regardless of hospitalization. For similar errors, verify formulations against prescriptions. Reporting promotes inventory distinctions.

Question 4

1. Incorrect dose: lamotrigine titration should be reduced with valproic acid to decrease serious rash risk; failure to adjust is a reportable error (correct answer)
2. Wrong drug dispensed: lamotrigine should be replaced with lithium for all bipolar patients
3. Monitoring oversight: serum sodium should be monitored weekly with lamotrigine
4. Documentation error: recording weight is prohibited in psychiatric patients

Explanation: Medication error identification and reporting include failures in adjusting titration for interacting anticonvulsants to minimize rash risks. The key patient-specific factor is using standard lamotrigine titration with valproic acid, which inhibits lamotrigine clearance and increases rash likelihood. Choice A best addresses the error as it identifies the incorrect titration dose, making it reportable. Choice B is incorrect because lithium substitution isn't standard, and choice C is suboptimal as sodium monitoring isn't routine for lamotrigine. Choice D is wrong since weight recording is appropriate. For similar errors, consult interaction-specific guidelines. Reporting enhances dispensing checklists.

Question 5

1. Monitoring oversight: failure to provide essential administration counseling for alendronate leading to preventable harm (correct answer)
2. Wrong drug dispensed: alendronate should be replaced with calcitonin nasal spray in all patients
3. Incorrect dose: alendronate 70 mg weekly is always too high for adults
4. Misidentification: esophageal irritation is unrelated to alendronate and should not be documented

Explanation: Medication error identification and reporting encompass inadequate counseling on administration techniques for drugs with specific requirements to prevent local harm. The key patient-specific factor is the lack of education on upright positioning and fasting with alendronate, leading to esophageal irritation. Choice A best addresses the error as it identifies the monitoring oversight in counseling, causing preventable harm. Choice B is incorrect because alendronate is appropriate for steroid-induced osteoporosis, and choice C is suboptimal as the dose is standard. Choice D is wrong since esophageal irritation is a known alendronate risk. In practice, provide written and verbal instructions for bisphosphonates. Reporting supports counseling standardization.

Question 6

1. Advise the patient to double the warfarin dose to overcome the interaction
2. Contact the prescriber urgently to manage supratherapeutic INR and the warfarin–fluconazole interaction, ensure appropriate monitoring, and document/report the interaction oversight (correct answer)
3. Stop fluconazole and instruct the patient to self-treat with over-the-counter antifungals without follow-up
4. Document the INR value but take no further action because INR changes are expected

Explanation: Medication error identification and reporting focus on unmanaged interactions causing coagulopathy in anticoagulated patients. The key patient-specific factor is fluconazole's inhibition of warfarin metabolism, leading to supratherapeutic INR without planned monitoring. Choice B best addresses the error by urging prescriber contact for management and reporting the oversight. Choice A is incorrect as doubling warfarin would worsen bleeding risk, and choice C is suboptimal without ensuring infection resolution. Choice D is wrong since action is needed beyond documentation. In practice, arrange prompt INR checks for interacting additions. Reporting improves follow-up protocols.

Question 7

1. Monitoring oversight: interacting antibiotic was prescribed without arranging timely international normalized ratio monitoring or warfarin dose adjustment plan (correct answer)
2. Misidentification: the error is that the target international normalized ratio should be 1–2 for atrial fibrillation
3. Wrong procedure: instruct the patient to stop warfarin for 10 days and do not document because this is a routine interaction
4. Irrelevant action: report amiodarone as a dispensing error because it can increase international normalized ratio

Explanation: This scenario involves a monitoring oversight error where an antibiotic known to significantly increase warfarin effect was prescribed without appropriate INR monitoring plans. The key patient-specific factor is the patient's therapeutic anticoagulation with warfarin (INR 2.4) for atrial fibrillation, which will be dangerously potentiated by trimethoprim-sulfamethoxazole's inhibition of warfarin metabolism. Option A correctly identifies this as a monitoring oversight requiring immediate reporting, as the prescriber failed to arrange timely INR checks or provide warfarin dose adjustment guidance during antibiotic therapy. Option B is incorrect because the INR target of 2-3 is appropriate for atrial fibrillation, not 1-2. Option C is wrong and dangerous, as stopping warfarin abruptly could lead to stroke, and all significant interactions must be documented. Option D is incorrect because amiodarone is appropriately prescribed and monitored; the acute issue is the new antibiotic interaction. The framework for managing drug interaction errors includes: (1) identifying high-risk combinations at dispensing, (2) contacting prescribers for monitoring plans, (3) educating patients on signs of over-anticoagulation, (4) scheduling follow-up INR checks, and (5) documenting interventions in the patient record and error reporting systems.

Question 8

1. Document the incorrect formulation, lot number, patient notification, prescriber notification, corrective action (recall/replace), and internal error report per policy (correct answer)
2. Document only that the patient was dissatisfied with the appearance of the tablets
3. Document that the error was unavoidable and therefore should not be reported
4. Document the event only after the next refill to confirm it happens again

Explanation: Medication error identification and reporting require thorough documentation of dispensing errors, including corrective actions, to ensure accountability and prevention. The key patient-specific factor is the mislabeling and dispensing of immediate-release morphine instead of extended-release, risking overdose or inadequate pain control. Choice A best addresses the error by outlining comprehensive documentation of the error details, notifications, and actions per policy. Choice B is incorrect as it minimizes the error to patient dissatisfaction, and choice C is suboptimal by excusing the error. Choice D is wrong since immediate reporting is needed. For similar errors, follow recall procedures and patient outreach. Reporting builds robust error-tracking systems.

Question 9

1. Misidentification: gabapentin is contraindicated with oxycodone due to a pharmacokinetic interaction
2. Incorrect prioritization: the main issue is that diazepam should be taken with food to reduce nausea
3. Interaction oversight: benzodiazepine was added to chronic opioid therapy without addressing additive respiratory depression risk and safety measures (e.g., prescriber contact, counseling, documentation/reporting) (correct answer)
4. Wrong procedure: fill as written and advise the patient to double oxycodone for breakthrough pain, then report only if an overdose occurs

Explanation: This case demonstrates an interaction oversight error involving the dangerous combination of benzodiazepines with chronic opioid therapy without appropriate risk mitigation. The key patient-specific factor is the patient's chronic opioid use (oxycodone 3-4 times daily) now combined with diazepam, manifesting as respiratory depression (excessive sedation and slowed breathing). Option C correctly identifies this as an interaction oversight requiring immediate intervention, as the prescriber failed to address the additive CNS depression risk or implement safety measures like naloxone co-prescribing. Option A is incorrect because gabapentin and oxycodone don't have a significant pharmacokinetic interaction; the issue is the new benzodiazepine addition. Option B is wrong as taking diazepam with food for nausea is not the critical safety issue here. Option D is dangerously incorrect, advocating for increased opioid use and delayed reporting, which could result in fatal overdose. The framework for managing opioid-benzodiazepine combinations includes: (1) identifying all patients on chronic opioids before adding benzodiazepines, (2) implementing dose reductions when combination is necessary, (3) co-prescribing naloxone, (4) enhanced monitoring for respiratory depression, and (5) documenting risk-benefit discussions and safety measures.

Question 10

1. The patient's insurance formulary status for nitrofurantoin to determine if a substitution is allowed
2. Prescriber identifiers (name, National Provider Identifier, and contact information) and clarification of the intended medication and directions before dispensing and documenting the event (correct answer)
3. A pregnancy test result because nitrofurantoin is contraindicated in all trimesters
4. A repeat serum creatinine in 24 hours to determine if the prescription is valid

Explanation: This scenario involves an incomplete prescription that lacks critical prescriber identification information required for legal dispensing and error reporting. The key patient-specific factor is the missing prescriber identifiers (NPI and contact information) combined with an illegible signature, making it impossible to verify the prescription's authenticity or contact the prescriber for clarification. Option B correctly identifies that prescriber identifiers and clarification of the intended medication are essential before dispensing and for proper error documentation. Option A is incorrect because insurance formulary status is irrelevant when the prescription itself is incomplete and potentially invalid. Option C is wrong because nitrofurantoin is generally safe in early pregnancy and contraindicated only in the third trimester; pregnancy testing is not required for dispensing. Option D is incorrect as the serum creatinine is normal and repeat testing won't resolve the prescriber identification issue. The framework for managing incomplete prescription errors includes: (1) never dispensing without complete prescriber information, (2) attempting to identify the prescriber through other means, (3) documenting all attempts to clarify prescriptions, (4) reporting patterns of incomplete prescriptions, and (5) educating prescribers about legal requirements for valid prescriptions.

Question 11

1. Interaction oversight/duplicate effect: potassium supplementation was continued despite hyperkalemia and use of spironolactone and lisinopril (correct answer)
2. Wrong drug dispensed: spironolactone should be replaced with furosemide in all patients
3. Monitoring oversight: failure to obtain baseline INR before starting lisinopril
4. Misidentification: potassium 5.6 mEq/L is within normal limits in heart failure

Explanation: Medication error identification and reporting include duplicate therapies causing electrolyte imbalances in heart failure patients. The key patient-specific factor is continuing potassium supplementation with hyperkalemia and potassium-sparing agents like spironolactone and lisinopril. Choice A best addresses the error as it points to the oversight of additive hyperkalemic effects, risking arrhythmias. Choice B is incorrect because spironolactone is appropriate in heart failure, and choice C is suboptimal as INR isn't relevant for lisinopril. Choice D is wrong since potassium 5.6 mEq/L indicates hyperkalemia. For similar errors, review profiles for additive effects and adjust accordingly. Reporting informs guidelines for electrolyte management.

Question 12

1. Monitoring oversight: failure to ensure appropriate patient education/monitoring for severe antibiotic-associated diarrhea and prompt follow-up (correct answer)
2. Wrong drug dispensed: clindamycin should never be used for dental infections
3. Incorrect dose: clindamycin 300 mg four times daily is always an overdose in adults
4. Interaction oversight: oral contraceptives are completely ineffective with clindamycin and must be discontinued

Explanation: Medication error identification and reporting include failures in patient education for high-risk side effects like antibiotic-associated diarrhea to enable timely intervention. The key patient-specific factor is the lack of counseling on recognizing and seeking care for severe diarrhea with clindamycin, a high-risk agent for C. difficile. Choice A best addresses the error as it points to inadequate monitoring and education, contributing to delayed care for potential complications. Choice B is incorrect because clindamycin is appropriate for dental infections in some cases, and choice C is suboptimal as the dose is within guidelines. Choice D is wrong since clindamycin doesn't render oral contraceptives ineffective. For similar errors, provide standardized counseling on key risks and follow-up needs. Reporting supports development of educational tools and checklists.

Question 13

1. Dispense ketoconazole and advise the patient to separate doses by 2 hours to avoid the interaction
2. Contact the prescriber because ketoconazole can significantly increase apixaban exposure; recommend an alternative antifungal or apixaban adjustment per labeling and document/report the interaction oversight (correct answer)
3. Stop apixaban immediately and instruct the patient to take aspirin 325 mg daily instead
4. Report the event only to the medication manufacturer because it is an adverse drug reaction, not an error

Explanation: Medication error identification and reporting involve intervening in potent interactions for anticoagulants to prevent bleeding risks. The key patient-specific factor is ketoconazole's strong CYP3A4 inhibition increasing apixaban exposure in a patient on diltiazem, another inhibitor. Choice B best addresses the error by recommending prescriber contact for alternatives or adjustments and reporting the oversight. Choice A is incorrect as dose separation doesn't mitigate this interaction, and choice C is suboptimal because switching to aspirin ignores atrial fibrillation needs. Choice D is wrong since this is an error, not just an adverse reaction. In practice, use interaction tools and hold dispensing until resolved. Reporting enhances safety nets for high-risk combinations.

Question 14

1. Continue hydralazine as dispensed and counsel the patient to monitor blood pressure more frequently
2. Contact the prescriber and patient immediately, correct the wrong-drug dispensing (hydralazine vs hydroxyzine), assess for harm, and document/report per pharmacy policy (correct answer)
3. Submit an external report only if the patient is hospitalized; otherwise no documentation is needed
4. Switch the patient to diphenhydramine over-the-counter and void the prescription without notifying the prescriber

Explanation: This case illustrates a wrong-drug dispensing error where hydralazine (an antihypertensive) was dispensed instead of the prescribed hydroxyzine (an antihistamine/anxiolytic). The key patient-specific factor is that the patient is already hypotensive (104/62 mmHg) and taking hydralazine, making additional antihypertensive medication particularly dangerous. Option B correctly outlines the comprehensive response: immediate prescriber and patient contact, assessment for harm, correction of the error, and formal documentation/reporting per pharmacy policy. Option A is incorrect because continuing the wrong medication could cause severe hypotension and harm. Option C is wrong because all medication errors require internal documentation and reporting regardless of hospitalization status. Option D is inappropriate as it involves changing therapy without prescriber authorization and fails to address the dispensing error properly. The framework for managing wrong-drug errors includes: (1) immediate cessation of the incorrect medication, (2) rapid patient assessment for harm, (3) prescriber notification, (4) dispensing the correct medication, (5) comprehensive documentation in error reporting systems, and (6) root cause analysis to prevent similar look-alike/sound-alike errors.

Question 15

1. Document that no action is needed because abnormal triglycerides are unrelated to isotretinoin therapy
2. Document only the patient's complaint of acne severity and dispense as written
3. Document the missing monitoring plan (lipids and liver enzymes), communication with prescriber, and the disposition (held/clarified) per pharmacy error-reporting policy (correct answer)
4. Document the issue only in a personal notebook to avoid creating a legal record

Explanation: Medication error identification and reporting require documenting failures in required monitoring for teratogenic drugs like isotretinoin to ensure compliance and prevent harm. The key patient-specific factor is the absence of a documented baseline monitoring plan for lipids and liver enzymes despite abnormal labs, violating isotretinoin safety protocols. Choice C best addresses the error by emphasizing documentation of the missing plan, prescriber communication, and disposition to adhere to error-reporting policies. Choice A is incorrect as abnormal triglycerides are a known isotretinoin risk requiring monitoring, and choice B is suboptimal by ignoring safety monitoring. Choice D is wrong since personal notebooks avoid formal records needed for accountability. For similar errors, verify REMS requirements before dispensing and collaborate with prescribers. Reporting enhances systemic adherence to risk management programs.

Question 16

1. Interaction oversight: TMP-SMX can worsen hyperkalemia with lisinopril and spironolactone; pharmacist should intervene, arrange monitoring/alternative, and document/report (correct answer)
2. Omission error: failure to add potassium chloride to prevent hypokalemia
3. Wrong procedure: document the concern only if potassium exceeds 6.5 mEq/L
4. Misidentification: potassium 5.2 mEq/L is always normal and requires no action

Explanation: Medication error identification and reporting involve recognizing deviations from safe prescribing, dispensing, or administration practices to prevent patient harm and improve healthcare systems. In this case, the key patient-specific factor is the concurrent use of lisinopril and spironolactone, which already elevate potassium levels to 5.2 mEq/L, combined with TMP-SMX's potential to further increase hyperkalemia risk. Choice A best addresses the error by highlighting the pharmacist's oversight in not intervening to monitor, adjust therapy, or report the interaction, which is critical for patient safety. Choice B is incorrect as it suggests an omission of potassium supplementation, but the risk here is hyperkalemia, not hypokalemia; choice C is suboptimal because action should be taken proactively rather than waiting for severe hyperkalemia above 6.5 mEq/L. Choice D is wrong as potassium 5.2 mEq/L is elevated and requires attention, not dismissal as normal. A transferable clinical framework includes routinely screening for drug interactions using tools like electronic health records and involving multidisciplinary teams for timely interventions. For similar errors, pharmacists should document incidents in reporting systems like ISMP or FDA MedWatch to facilitate root cause analysis and prevent recurrence.

Question 17

1. Monitoring oversight: failure to arrange/document appropriate follow-up triglycerides and liver function monitoring while on isotretinoin (correct answer)
2. Misidentification: the primary error is that isotretinoin is contraindicated in all male patients
3. Incomplete action: counsel the patient to avoid fatty foods but do not notify the prescriber or document the event
4. Wrong procedure: report the event only to the medication manufacturer and not within the health system because it is a known adverse effect

Explanation: This scenario illustrates a monitoring oversight error where required laboratory monitoring for a high-risk medication was not arranged or documented. The key patient-specific factor is the baseline elevated triglycerides (210 mg/dL) before starting isotretinoin, which is known to cause significant lipid elevations requiring regular monitoring. Option A correctly identifies this as a monitoring oversight, as the failure to arrange follow-up triglyceride and liver function tests led to the patient developing severe hypertriglyceridemia (980 mg/dL) with associated pancreatitis risk. Option B is incorrect because isotretinoin is not contraindicated in males; the primary contraindication is in females of childbearing potential due to teratogenicity. Option C is wrong because this serious monitoring failure requires prescriber notification and system reporting, not just dietary counseling. Option D is incorrect as this represents a system failure requiring internal health system reporting to prevent recurrence, not just manufacturer notification. The framework for preventing monitoring errors includes: (1) establishing mandatory baseline labs for high-risk drugs, (2) creating automatic monitoring reminders in the system, (3) documenting monitoring plans clearly, (4) educating patients about required follow-up, and (5) implementing fail-safe systems for critical lab values.

Question 18

1. Incorrect dose: levofloxacin was prescribed without renal adjustment for creatinine clearance 22 mL/min (correct answer)
2. Irrelevant action: discontinue lisinopril immediately because it increases serum creatinine
3. Misidentification: the main error is the lack of liver function tests before starting levofloxacin
4. Overlooking: the only issue is calcium carbonate causing constipation, which should be reported as a dispensing error

Explanation: This scenario demonstrates a medication error involving failure to adjust antibiotic dosing for impaired renal function. The key patient-specific factor is the severely reduced creatinine clearance of 22 mL/min, which requires significant dose reduction for renally eliminated medications like levofloxacin. Option A correctly identifies this as an incorrect dose error, as levofloxacin 750 mg daily is excessive for this degree of renal impairment and could lead to toxicity, including QT prolongation and tendinopathy. Option B is incorrect because lisinopril causing mild creatinine elevation is expected and not the primary concern requiring immediate action. Option C is wrong because liver function tests are not routinely required before levofloxacin, and the provided AST is normal. Option D is incorrect as calcium carbonate causing constipation is a minor side effect, not a reportable dispensing error, and misses the critical renal dosing issue. The framework for preventing renal dosing errors includes: (1) calculating creatinine clearance for all patients, (2) checking drug references for renal adjustments, (3) flagging high-risk medications in the system, (4) documenting dose adjustments clearly, and (5) establishing mandatory pharmacist review for renally eliminated drugs.

Question 19

1. Dispense as written because nitrofurantoin is safe at any renal function if used short-term
2. Contact the prescriber to recommend an alternative agent due to reduced efficacy and increased risk with creatinine clearance 28 mL/min, and document/report the renal dosing oversight (correct answer)
3. Add trimethoprim-sulfamethoxazole for broader coverage despite sulfonamide allergy
4. Report the event only if the patient experiences an adverse reaction

Explanation: Medication error identification and reporting address inappropriate drug selection in renal impairment to ensure efficacy and safety. The key patient-specific factor is creatinine clearance of 28 mL/min, where nitrofurantoin has reduced efficacy and increased toxicity risk. Choice B best addresses the error by recommending prescriber contact for alternatives and reporting the dosing oversight. Choice A is incorrect as nitrofurantoin isn't safe short-term below 30 mL/min, and choice C is suboptimal due to sulfonamide allergy. Choice D is wrong since proactive reporting prevents harm. In practice, assess renal function against contraindications before dispensing. Reporting strengthens checks for at-risk populations.

Question 20

1. Incorrect dose: gabapentin was not adjusted for creatinine clearance 18 mL/min, increasing risk of central nervous system toxicity (correct answer)
2. Wrong drug dispensed: gabapentin should be substituted with pregabalin without prescriber approval
3. Omission error: failure to add ibuprofen for pain control
4. Documentation error: weight is not needed for gabapentin dosing and should not be recorded

Explanation: Medication error identification and reporting highlight unadjusted dosing in renal impairment for drugs like gabapentin to avert accumulation and toxicity. The key patient-specific factor is the creatinine clearance of 18 mL/min, necessitating a reduced gabapentin dose to prevent CNS effects. Choice A best addresses the error as it identifies the incorrect dose without renal adjustment, increasing toxicity risk. Choice B is incorrect because substituting with pregabalin requires prescriber approval, and choice C is suboptimal as ibuprofen addition isn't indicated without pain assessment. Choice D is wrong since weight is useful but not essential for gabapentin dosing. In practice, calculate renal function for all relevant prescriptions and consult dosing guidelines. Reporting fosters pharmacy protocols for mandatory renal checks.